Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences



 Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences

PR Newswire

RICHMOND, Calif., Feb. 7, 2013

RICHMOND, Calif., Feb. 7, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc.
(Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and
CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic^®
development programs and an overview of the company's business strategy at the
following conferences:

  o The Leerink Swann Global Healthcare Conference in New York. 
    Presentation at 11:30 am ET, on Thursday, February 14, 2013.
  o The RBC Capital Markets Healthcare Conference in New York.
    Presentation at 10:30 am ET on Wednesday, February 27, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentations will be webcast live and may be accessed via a link on the
Sangamo BioSciences website in the Investor Relations section
http://investor.sangamo.com/index.cfm under Events and Presentations. The
presentation will be archived on the Sangamo website for two weeks after the
event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel
DNA-binding proteins for therapeutic gene regulation and genome editing. The
Company has ongoing Phase 2 clinical trials to evaluate the safety and
efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's
other therapeutic programs are focused on monogenic diseases, including
hemophilia, Huntington's disease and  hemoglobinopathies such as
beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable
the engineering of a class of DNA-binding proteins known as zinc finger
DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific
DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs)
for gene modification and ZFP transcription factors (ZFP TFs) that can control
gene expression and, consequently, cell function. Sangamo has entered into a
strategic collaboration with Shire AG to develop therapeutics for hemophilia,
Huntington's disease and other monogenic diseases and has established
strategic partnerships with companies in non-therapeutic applications of its
technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more
information about Sangamo, visit the Company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.

Website: http://www.sangamo.com
Contact: Elizabeth Wolffe, Ph.D, +1-510-970-6000, ext. 271,
ewolffe@sangamo.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement